TG THERAPEUTICS INC's ticker is TGTX and the CUSIP is 88322Q108. A total of 216 filers reported holding TG THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.63 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,352,863 | -66.1% | 1,357,998 | +0.7% | 0.00% | -66.7% |
| Q2 2023 | $33,504,193 | +71.1% | 1,348,800 | +3.6% | 0.01% | +50.0% |
| Q1 2023 | $19,578,575 | +30.2% | 1,301,767 | +2.4% | 0.00% | +33.3% |
| Q4 2022 | $15,033,540 | +102.4% | 1,270,798 | +1.3% | 0.00% | +50.0% |
| Q3 2022 | $7,428,000 | +40.4% | 1,254,793 | +0.8% | 0.00% | +100.0% |
| Q2 2022 | $5,290,000 | -55.6% | 1,244,889 | -0.6% | 0.00% | -50.0% |
| Q1 2022 | $11,914,000 | -52.1% | 1,252,719 | -4.3% | 0.00% | -50.0% |
| Q4 2021 | $24,867,000 | -43.2% | 1,308,770 | -0.4% | 0.00% | -50.0% |
| Q3 2021 | $43,743,000 | -17.3% | 1,314,420 | -3.6% | 0.01% | -11.1% |
| Q2 2021 | $52,917,000 | -17.7% | 1,364,197 | +2.2% | 0.01% | -25.0% |
| Q1 2021 | $64,327,000 | -8.7% | 1,334,593 | -1.5% | 0.01% | -14.3% |
| Q4 2020 | $70,464,000 | +95.7% | 1,354,558 | +0.7% | 0.01% | +75.0% |
| Q3 2020 | $35,997,000 | +45.7% | 1,345,179 | +6.1% | 0.01% | +33.3% |
| Q2 2020 | $24,706,000 | +125.4% | 1,268,256 | +13.8% | 0.01% | +100.0% |
| Q1 2020 | $10,963,000 | -9.0% | 1,114,099 | +2.7% | 0.00% | 0.0% |
| Q4 2019 | $12,047,000 | +102.4% | 1,085,305 | +2.4% | 0.00% | +200.0% |
| Q3 2019 | $5,952,000 | -18.4% | 1,060,110 | +25.7% | 0.00% | -50.0% |
| Q2 2019 | $7,293,000 | +12.0% | 843,143 | +4.1% | 0.00% | 0.0% |
| Q1 2019 | $6,512,000 | +98.1% | 809,943 | +1.0% | 0.00% | +100.0% |
| Q4 2018 | $3,287,000 | -28.6% | 801,560 | -2.5% | 0.00% | 0.0% |
| Q3 2018 | $4,606,000 | -53.4% | 822,439 | +9.4% | 0.00% | -66.7% |
| Q2 2018 | $9,885,000 | +10.4% | 751,725 | +19.3% | 0.00% | +50.0% |
| Q1 2018 | $8,951,000 | +76.7% | 630,301 | +2.0% | 0.00% | +100.0% |
| Q4 2017 | $5,066,000 | -28.4% | 617,784 | +3.5% | 0.00% | -50.0% |
| Q3 2017 | $7,073,000 | +17.6% | 596,898 | -0.3% | 0.00% | 0.0% |
| Q2 2017 | $6,016,000 | +11.3% | 598,626 | +29.0% | 0.00% | 0.0% |
| Q1 2017 | $5,407,000 | +153.8% | 464,163 | +1.3% | 0.00% | +100.0% |
| Q4 2016 | $2,130,000 | -39.5% | 458,210 | +0.8% | 0.00% | 0.0% |
| Q3 2016 | $3,519,000 | +26.2% | 454,721 | -1.2% | 0.00% | 0.0% |
| Q2 2016 | $2,789,000 | -26.8% | 460,288 | +3.0% | 0.00% | 0.0% |
| Q1 2016 | $3,810,000 | -27.7% | 447,094 | +1.2% | 0.00% | -50.0% |
| Q4 2015 | $5,272,000 | +22.7% | 441,915 | +3.6% | 0.00% | +100.0% |
| Q3 2015 | $4,298,000 | -28.2% | 426,363 | +18.2% | 0.00% | -50.0% |
| Q2 2015 | $5,982,000 | +25.8% | 360,640 | +17.4% | 0.00% | +100.0% |
| Q1 2015 | $4,756,000 | -0.1% | 307,203 | +2.2% | 0.00% | 0.0% |
| Q4 2014 | $4,759,000 | +74.3% | 300,491 | +17.4% | 0.00% | 0.0% |
| Q3 2014 | $2,731,000 | +30.3% | 256,009 | +14.7% | 0.00% | 0.0% |
| Q2 2014 | $2,096,000 | +39.1% | 223,292 | +2.2% | 0.00% | – |
| Q1 2014 | $1,507,000 | +81.1% | 218,428 | +2.4% | 0.00% | – |
| Q4 2013 | $832,000 | -18.6% | 213,326 | +5.2% | 0.00% | – |
| Q3 2013 | $1,022,000 | +131.7% | 202,809 | +193.8% | 0.00% | – |
| Q2 2013 | $441,000 | – | 69,034 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Opaleye Management Inc. | 1,890,000 | $15,800,400 | 5.14% |
| Ghost Tree Capital, LLC | 1,000,000 | $8,360,000 | 2.75% |
| Soleus Capital Management, L.P. | 2,884,382 | $24,113,434 | 2.22% |
| M28 Capital Management LP | 216,600 | $1,810,776 | 2.08% |
| Paradigm Biocapital Advisors LP | 3,619,015 | $30,254,965 | 2.05% |
| 683 Capital Management, LLC | 1,350,000 | $11,286,000 | 0.88% |
| Parkwood LLC | 165,414 | $6,081 | 0.66% |
| Spotlight Asset Group, Inc. | 79,000 | $660,440 | 0.60% |
| Pier Capital, LLC | 392,709 | $3,283,047 | 0.53% |
| Quantum Private Wealth, LLC | 91,081 | $761,438 | 0.36% |